RB 81 Pill - pink oval, 10mm
Pill with imprint RB 81 is Pink, Oval and has been identified as Zolpidem Tartrate 5 mg. It is supplied by Ranbaxy Pharmaceuticals Inc.
Zolpidem is used in the treatment of Insomnia and belongs to the drug class miscellaneous anxiolytics, sedatives and hypnotics. Risk cannot be ruled out during pregnancy. Zolpidem 5 mg is classified as a Schedule 4 controlled substance under the Controlled Substance Act (CSA).
Images for RB 81
Zolpidem Tartrate
- Imprint
- RB 81
- Strength
- 5 mg
- Color
- Pink
- Size
- 10.00 mm
- Shape
- Oval
- Availability
- Prescription only
- Drug Class
- Miscellaneous anxiolytics, sedatives and hypnotics
- Pregnancy Category
- C - Risk cannot be ruled out
- CSA Schedule
- 4 - Some potential for abuse
- Labeler / Supplier
- Ranbaxy Pharmaceuticals Inc.
- National Drug Code (NDC)
- 63304-0159 (Discontinued)
- Inactive Ingredients
-
silicon dioxide,
ferric oxide red,
hypromelloses,
lactose monohydrate,
magnesium stearate,
microcrystalline cellulose,
polyethylene glycol,
sodium starch glycolate type A potato,
magnesium silicate,
titanium dioxide
Note: Inactive ingredients may vary.
Related images for "RB 81"
More about zolpidem
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (1,049)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Support group
- Drug class: miscellaneous anxiolytics, sedatives and hypnotics
- Breastfeeding
- En español
Patient resources
- Zolpidem drug information
- Zolpidem (Oromucosal, Sublingual) (Advanced Reading)
- Zolpidem Extended-Release Tablets
- Zolpidem Sublingual Tablets (Edluar)
- Zolpidem Sublingual Tablets (Intermezzo)
Other brands
Ambien, Ambien CR, Zolpimist, Intermezzo, Edluar
Professional resources
- Zolpidem monograph
- Zolpidem (FDA)
- Zolpidem Capsule (FDA)
- Zolpidem Extended Release (FDA)
- Zolpidem Sublingual (FDA)
Other brands
Ambien, Ambien CR, Zolpimist, Intermezzo, Edluar
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
